Literature DB >> 19699305

A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats.

Jana Boy1, Thorsten Schmidt, Ulrike Schumann, Ute Grasshoff, Samy Unser, Carsten Holzmann, Ina Schmitt, Tim Karl, Franco Laccone, Hartwig Wolburg, Saleh Ibrahim, Olaf Riess.   

Abstract

Spinocerebellar ataxia type 3 (SCA3), or Machado-Joseph disease (MJD), is caused by the expansion of a polyglutamine repeat in the ataxin-3 protein. We generated a mouse model of SCA3 expressing ataxin-3 with 148 CAG repeats under the control of the huntingtin promoter, resulting in ubiquitous expression throughout the whole brain. The model resembles many features of the disease in humans, including a late onset of symptoms and CAG repeat instability in transmission to offspring. We observed a biphasic progression of the disease, with hyperactivity during the first months and decline of motor coordination after about 1 year of age; however, intranuclear aggregates were not visible at this age. Few and small intranuclear aggregates appeared first at the age of 18 months, further supporting the claim that neuronal dysfunction precedes the formation of intranuclear aggregates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699305     DOI: 10.1016/j.nbd.2009.08.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  26 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

Review 3.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

4.  Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Authors:  Ilya Bezprozvanny; Thomas Klockgether
Journal:  Drugs Future       Date:  2009-12       Impact factor: 0.148

Review 5.  Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).

Authors:  Veronica F Colomer Gould
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

6.  Interaction between the AAA+ ATPase p97 and its cofactor ataxin3 in health and disease: Nucleotide-induced conformational changes regulate cofactor binding.

Authors:  Maya V Rao; Dewight R Williams; Simon Cocklin; Patrick J Loll
Journal:  J Biol Chem       Date:  2017-09-22       Impact factor: 5.157

7.  Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.

Authors:  Vitor Carmona; Janete Cunha-Santos; Isabel Onofre; Ana Teresa Simões; Udaya Vijayakumar; Beverly L Davidson; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2017-02-22       Impact factor: 11.454

8.  Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Mariana Conceição; Nicole Déglon; Luís Pereira de Almeida
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

9.  Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.

Authors:  Anabela Silva-Fernandes; Sara Duarte-Silva; Andreia Neves-Carvalho; Marina Amorim; Carina Soares-Cunha; Pedro Oliveira; Kenneth Thirstrup; Andreia Teixeira-Castro; Patrícia Maciel
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

10.  Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.

Authors:  Anna Sergeevna Sowa; Elodie Martin; Inês Morgado Martins; Jana Schmidt; Reinhard Depping; Jonasz Jeremiasz Weber; Franziska Rother; Enno Hartmann; Michael Bader; Olaf Riess; Hervé Tricoire; Thorsten Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.